Strategic Targeting Focus outreach to biopharma and CROs active in IBD and oncology development, highlighting TP-317’s first-in-class oral Resolvin E1 mechanism targeting BLT1 to address ulcerative colitis, Crohn's disease, and solid tumors with high unmet need.

Clinical Momentum Leverage ongoing clinical activities and recent data presentations at IBD Innovate and ECCO 2025 to engage potential partners, investors, and contract manufacturers by showcasing preclinical and early clinical progress and the Phase 1b advancement in ulcerative colitis.

Strategic Partnerships Promote opportunities for collaboration or minority investments with family offices and philanthropic funds (e.g., Helmsley Charitable Trust) that support translational retinal therapeutics pipelines, emphasizing non-dilutive funding and milestone-driven partnerships.

Board & Advisory Highlight recent board and scientific advisory appointments to signal governance strength and scientific rigor, using these milestones to reassure potential investors and strategic partners about oversight and expertise.

Funding Levers Position Thetis as an attractive partner for co-development, licensing, or milestone-based collaboration by citing the $32M funding backbone and $8.98M program-related investment, aligning opportunities with near-term Phase 1b readiness and scalable manufacturing.